title: Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.
abstract: Interferon-beta (IFNbeta) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNbeta to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsing-remitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNbeta-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNbeta therapy. The decrease was greater (P = 0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNbeta-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNbeta appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.
authors.affiliation: Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: J M
authors.initials: JM
authors.lastname: Solomon
authors.forename: T A
authors.initials: TA
authors.lastname: Tasciyan
authors.forename: M M
authors.initials: MM
authors.lastname: Cao
authors.forename: R D
authors.initials: RD
authors.lastname: Stone
authors.forename: J L
authors.initials: JL
authors.lastname: Ostuni
authors.forename: J M
authors.initials: JM
authors.lastname: Ohayon
authors.forename: P A
authors.initials: PA
authors.lastname: Muraro
authors.forename: J A
authors.initials: JA
authors.lastname: Frank
authors.forename: N D
authors.initials: ND
authors.lastname: Richert
authors.forename: H F
authors.initials: HF
authors.lastname: McFarland
authors.forename: F
authors.initials: F
authors.lastname: Bagnato
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta